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Abstract
Background: Infections in cirrhotic patients with upper gastrointestinal bleeding are a common event causing
severe complication and mortality. This study aimed to identify risk factors that may predict rebleeding, bacterial
infections, and the impact of antibiotic prophylaxis on mortality at different stages of cirrhosis following acute
peptic ulcer bleeding (PUB).
Methods: A hospital-based retrospective cohort study was conducted on 235 cirrhotic patients with acute peptic
ulcer hemorrhage who underwent therapeutic endoscopic procedures between January 2008 and January 2014
(n = 235); of these, 88 patients received prophylactic intravenous ceftriaxone (antibiotic group) and 147 patients did
not (nil-antibiotic group). The recorded outcomes were length of hospital stay, bacterial infection, rebleeding, and
in-hospital mortality.
Results: Forty-eight (20.4 %) patients experienced ulcer rebleeding and 46 (19.6 %) developed bacterial infections.
More patients suffered from infection and recurrent bleeding in the nil-antibiotic group than the antibiotic group
(25.2 % vs. 10.2 %, p = 0.005 and 30.6 % vs. 3.4 %; p < 0.001, respectively). The predictive risk factors for rebleeding
were the Rockall score (p = 0.004), units of blood transfusion (p = 0.031), and no antibiotic prophylaxis (p <0.001);
for bacterial infections, they were the Child-Pugh score (p = 0.003), active alcoholism (p = 0.035), and no antibiotic
prophylaxis (p = 0.009). Overall, 40 (17 %) patients died during hospitalization. The Rockall score and rebleeding were
predictive factors for in-hospital mortality. In subgroup analysis, survival was significantly reduced in decompensated
patients (p = 0.034).
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Conclusions: This study suggests that antibiotic prophylaxis after endoscopic hemostasis for acute PUB prevented
infections and reduced rebleeding events in cirrhotic patients. Antibiotic prophylaxis improved survival among
decompensated cohort following PUB. The Rockall score and rebleeding were predictive risk factors for in-hospital
mortality.
Keywords: Liver cirrhosis, Peptic ulcer bleeding, Antibiotic prophylaxis, Bacterial infections, Rebleeding, In-hospital
mortality
Background
Upper gastrointestinal bleeding in cirrhotic patients is
associated with an increased rate of failure to control
bleeding and can result in mortality when bacterial
infections occur [1, 2]. This is evidenced by reports dem-
onstrating that oral administration of non-absorbable
antibiotics markedly reduces the incidence of bacterial
infections in cirrhotic patients with gastrointestinal he-
morrhage [3]. Patients with cirrhosis are at risk for both
variceal and nonvariceal causes of upper gastrointestinal
bleeding; however, only variceal bleeding has been widely
studied. Nevertheless, there remains one third of non-
variceal upper gastrointestinal bleeding in cirrhotic pa-
tients due to peptic ulcers (PU) as reported in the
literature [4]. In addition, bleeding PU have been associ-
ated with substantial morbidity and mortality in cirrhotic
patients [5]. A multicenter prospective study from Italy
reported that 10 % of patients with cirrhosis rebleed and
15 % of them died within 6 weeks after acute nonvariceal
upper gastrointestinal bleeding [5].
Bacterial infection is more prone to initiate a systemic
inflammatory response syndrome and increases the prob-
ability of death in patients with decompensated cirrhosis
[6]. Generally, cirrhotic patients with PUB become in-
fected and rebleed more frequently compared to non-
cirrhotic patients [4]. To our knowledge, prognosis after
treating acute PUB has not been well studied in cirrhotic
patients. Most studies on antibiotic prophylaxis in cir-
rhotic patients have focused on those with variceal hem-
orrhages [7–9]. Therefore, we conducted this study to
identify the risk factors that predict re-bleeding, bacterial
infections, mortality and the impact of antibiotic prophy-




This retrospective chart review study was approved by
both the Institutional Review Board and Ethics Commit-
tee of Chang Gung Memorial Hospital, Taiwan (IRB103-
5018B). The Ethics Committee waived the requirement
for informed consent, and each patient’s medical records
was anonymized and de-identified prior to access. All
patients provided their written inform consent before
endoscopic interventions.
Patient population
This was a hospital-based retrospective cohort study
including 426 cirrhotic eligible patients with PUB who
underwent endoscopic interventions over a 6 year period
between January 2008 and January 2014. The following
patients were excluded from the study: (1) presence of
any of the following signs of infection; fever >38 °C,
white blood cell count >10 000/mm3, immature neutro-
phils >500/mm3, a polymorphonuclear cell count in as-
citic fluid >250/mm3, ≥15 leukocytes/field in the fresh
urine sediment, or data compatible with pneumonia on
the chest X-ray (n = 105), (2) allergy to cephalosporins
(n = 2), (3) patients who received oral/parenteral antibi-
otics in the week prior to the procedure (n = 18), (4) a
source of upper gastrointestinal bleeding other than
PUB (n = 37), (5) patients who died within the first day
after admission (n = 3), (6) patients who did not complete
the in-hospital follow-up period (n = 26). A total of 235
patients were recruited into current study (male/female:
181/54; mean age: 62.2 ± 13.6 y). Those patients who re-
ceived prophylactic intravenous infusion of ceftriaxone at
1 g per 12 h were classified as the antibiotic group (n = 88)
in contrast to the control group who did not receive anti-
biotics (n = 147). The antibiotic group has been routine
practice to prescribe prophylactic antibiotics to cirrhotic
patients with gastrointestinal bleeding in our hospital
since the year 2010 according to guidelines. On the other
hand, those patients belonged to control group attended
the hospital between January 2008 and December 2009.
The antibiotic prophylaxis was given immediately after
patients receiving endoscopic treatment and two sets of
blood culture were obtained before administering the anti-
biotics even these patients did not encounter infections
according to our hospital policy.
PUB was defined by the existence of signs of hematem-
esis, coffee ground vomitus, hematochezia, or melena and
proven high-risk ulcers by endoscopy that were defined
according to the Forrest classification [10]. High risk
bleeding stigmata were referred for endoscopic view of
active bleeding, visible vessels, or adherent clots. Patients’
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performance status was stratified according to the Rockall
classification [11]. Blood transfusions were given to main-
tain hematocrit levels between 25 % and 30 %. Patients
with PUB were treated with intravenous high dose panto-
prazole (80 mg intravenous bolus followed by 200 mg
continuous infusion for three days).
Data collection and analysis
The first authors abstracted following information from
patient records (including written charts and electronic
data sources). All patients had a complete medical assess-
ment at initial hospital admission, including documenta-
tion of clinical, biochemical, and endoscopic factors that
might contribute to rebleeding and mortality. The regis-
tered clinical variables were demographic data, clinical
manifestations of bleeding, and the use of tobacco,
alcohol, aspirin, clopidogrel, and non-steroidal anti-
inflammatory drugs (NSAID); co-morbidities such as dia-
betes mellitus, cardiovascular disease, stroke, end-stage
renal disease, and chronic pulmonary disease were ana-
lyzed. Other clinical characteristics such as age, sex, and
hemodynamic instability on admission and laboratory
data such as white blood cell count, hemoglobin, platelet
count, prothrombin time, serum creatinine, serum albu-
min, and total bilirubin were analyzed. The recorded end-
points were occurrence of infection, rebleeding, length of
hospital stay, and in-hospital death.
Definitions
Time to endoscopy was defined as the time interval from
admission via the emergency department to initial endos-
copy, expressed in hours. The diagnosis of liver cirrhosis
was based on clinical, laboratory, abdominal ultrasono-
graphic, or histological findings [12]. Decompensated
liver cirrhosis was used to describe patients complicated
by ascites, jaundice (bilirubin level >3.0 mg/dl), and a his-
tory of identified varices or hepatic encephalopathy.
Diagnosis of hepatitis C and B virus-related liver disease
was determined with specific viral markers (HBsAg or
anti-HCV). Alcohol-related liver disease was defined as
daily alcohol consumption >80 g in men and >40 g in
women for at least 10 years with negative viral, meta-
bolic, and autoimmune markers [13]. Active alcoholism
is defined as a continuing daily alcohol intake over 20 g
in patients with alcoholic cirrhosis [13].
Rebleeding was defined as a new onset of hematemesis,
melena, or both associated with tachycardia or hypovol-
emic shock or a decrease in serum hemoglobin level of
>2 g/dl after successful endoscopic and pharmacological
treatment and hemodynamic stability of at least a 24 h
period of stable vital signs [14].
A diagnosis of bacteremia was made when the pres-
ence of viable bacteria in the blood and the clinical
picture was consistent with this diagnosis. The diagnosis
of spontaneous bacterial peritonitis was made when a
positive culture of ascitic fluid was obtained with an
ascitic fluid neutrophil count ≥250 neutrophils/μl [15].
The diagnosis of pneumonia was made by clinical, radio-
logical, and bacteriological data. The diagnosis of urinary
tract infection was made when a positive culture of urine
(105 ≥ colonies/ml) was obtained with a urine neutrophil
count >10 neutrophils/μl and associated clinical pictures.
Statistical analysis
All results were expressed as means ± standard deviations
for continuous variables and as relative frequencies or per-
centages for categorical variables. Distributions of con-
tinuous variables were analyzed by the X2 test, the Fisher’s
exact test, or the independent sample t-test, depending
upon the type of data analyzed for the two groups where
appropriate. The Kaplan–Meier analysis with the log-rank
test was used to compare differences of death rates be-
tween the two groups. Variables were analyzed using the
multivariate Cox proportional hazard model to determine
independent predictive factors of infection, rebleeding,
and mortality. All the variables in univariate analyses
were analyzed in multivariate analyses. The results were
expressed as a hazard ratio (HR) with 95 % confidence
intervals. All statistical analyses were performed using the
SPSS v18.0 (Chicago, Illinois, USA). A p-value of <0.05
was considered statistically significant.
Results
All the patients’ baseline characteristics are presented in
Table 1. All patients underwent emergency endoscopy
within 24 h of admission. The mean time from presenta-
tion of bleeding to endoscopy was 7.6 ± 7 h. One hundred
and forty-six patients (62.1 %) suffered from bleeding
gastric ulcers (GU), 73 (31.1 %) from duodenal ulcers
(DU), and 16 (6.8 %) from both GU and DU. These ulcers
had high risk stigmata of hemorrhage (Forrest Ia or Ib,
50.2 % and Forrest II a or IIb, 38.7 %). Among them,
57.4 % were found to have varices without stigmata of
recent hemorrhage [esophageal varices (EV): 51.4 %; gas-
tric varices (GV): 0.9 %; combined EV/GV: 5.1 %]. The
mean value of the Rockall scoring system was 4.7 ± 1.6
on admission.
The details of endoscopic interventions are also sum-
marized in Table 1. Endoscopic intervention was per-
formed on all patients with either monotherapy (65.5 %)
or combination therapy (34.5 %). All patients received
intravenous high dose proton pump inhibitors for 3 days
after initial endoscopic hemostasis. The mean length of
hospital stay was 14.9 ± 11.6 d. Patients in the antibiotic
group had a similar hospital stay when compared with
control patients (p = 0.282).
Overall, 48 (20.4 %) patients encountered rebleeding
events. Rebleeding rate in the antibiotic group was
Kuo et al. BMC Gastroenterology  (2015) 15:61 Page 3 of 13
significantly lower than the control group (3.4 % vs
30.6 %; p <0.001; Table 1). On multivariate analysis, the
risk factors for rebleeding were higher rockall score [HR =
1.069; 95 % confidence interval (CI) = 1.022–1.120; p =
0.004] and more units of blood transfusion (HR = 1.019;
95 % CI = 1.002–1.037; p = 0.031). Antibiotic prophylaxis
has a protective role for rebleeding in these patients
(HR = 0.082; 95 % CI = 0.025–0.267; p <0.001) (Table 2).
It is interesting that time to endoscopy, high risk
bleeding stigmata, and endoscopic therapeutic methods
were not associated with rebleeding rate (Table 2).
Bacterial infections were documented in 46 patients
(19.6 %); more patients were infected in the control
group (10.2 % vs. 25.2 %; p = 0.005). Infections were con-
firmed for 9 patients in the antibiotics group (bacteremia
in 4, spontaneous bacterial peritonitis in 2, pneumonia
in 1 and urinary tract infection in 2). On the other hand,
37 bacterial infections were proven in the control group
(bacteremia in 17, pneumonia in 4, spontaneous bac-
terial peritonitis in 10, and urinary tract infections in
6). The causative organisms of bacteremia were gram-
Table 1 Clinical characteristics, endoscopic findings, and







Age (y) 61.8 ± 15.2 62.5 ± 12.5 0.699
Male, n (%) 71 (80.7) 110 (74.8) 0.302
Etiology of liver cirrhosis
Alcoholic, n (%) 24 (27.3) 37 (25.2) 0.722
Viral hepatitis, n (%) 62 (70.4) 100 (68.0) 0.697
Cryptogenic, n (%) 2 (2.3) 10 (6.8) 0.219
Child-Pugh group
A, n (%) 40 (45.5) 68 (46.3) 0.905
B, n (%) 31 (35.2) 44 (29.9) 0.399
C, n (%) 17 (19.3) 35 (23.8) 0.422
Decompensated cirrhosis, n (%) 44 (50.0) 61 (41.5) 0.204
Rockall score 4.7 ± 1.5 4.7 ± 1.7 0.885
MELD score 13.7 ± 6.1 14.1 ± 6.0 0.631
Child-Pugh score 6.9 ± 1.5 7.1 ± 1.7 0.467
Gastroesophageal varices, n (%) 51 (58.0) 84 (57.1) 0.903
Ulcer location
Gastric ulcer, n (%) 55 (62.5) 91 (61.9) 0.927
Duodenal ulcer, n (%) 27 (30.7) 46 (31.3) 0.922
Both, n (%) 6 (6.8) 10 (6.8) 1
Use of NSAID or aspirin/
clopidogrel, n (%)
17 (19.3) 20 (13.6) 0.245
Smoking, n (%) 33 (37.5) 63 (42.9) 0.419
Active alcoholism, n (%) 31 (35.2) 55 (37.4) 0.736
Other comorbidities
Diabetes mellitus, n (%) 31 (35.2) 40 (27.2) 0.251
Hypertension, n (%) 39 (44.3) 54 (36.7) 0.311
Cardiovascular disease, n (%) 8 (9.1) 7 (4.8) 0.299
Stroke, n (%) 3 (3.4) 10 (6.8) 0.381
ESRD, n (%) 3 (3.4) 13 (8.8) 0.471
COPD, n (%) 8 (9.1) 7 (4.8) 0.269
Laboratory on admission
WBC (109/l) 6094.3 ± 2045.3 5876.2 ± 1970.4 0.419
Hb (g/dl) 8.7 ± 2.5 8.9 ± 1.9 0.437
PLT (109/l) 124.5 ± 60.5 121.5 ± 71.3 0.731
Prothrombin time (s) 13.6 ± 4.8 12.4 ± 2.7 0.031
Albumin (g/dl) 3.0 ± 0.7 2.8 ± 0.7 0.152
Creatinine (mg/dl) 1.6 ± 2.0 2.0 ± 2.5 0.126
Total bilirubin (mg/dl) 3.0 ± 3.8 3.1 ± 3.8 0.961
Clinical characteristics
Hypovolemic shock
on admission, n (%)
8 (9.1) 13 (8.8) 0.949
Blood units transfused
(unit)
4.8 ± 5.6 5.2 ± 7.6 0.637
Table 1 Clinical characteristics, endoscopic findings, and
clinical outcome of cirrhotic patients with peptic ulcer bleeding
(n = 235) (Continued)
Stigmata of recent
hemorrhage at ulcer
Forrest Ia or Ib ulcer, n (%) 44 (50) 74 (50.3) 0.960
Forrest IIa or IIb ulcer, n (%) 37 (42) 54 (36.7) 0.419
Forrest IIc ulcer, n (%) 7 (8) 19 (13) 0.240
Time (h), bleeding to
endoscopic treatment
6.9 ± 6.7 7.7 ± 6.6 0.382
Treatment
Epinephrine injection, n (%) 27 (30.7) 57 (38.8) 0.261
APC, n (%) 13 (14.8) 37 (25.2) 0.070
Hemoclipping, n (%) 14 (15.9) 6 (4.1) 0.003
Combined therapy, n (%) 34 (38.6) 47 (32.0) 0.323
Outcomes
Hospital stay (d) 15.7 ± 13.1 14.1 ± 10.9 0.282
Rebleeding, n (%) 3 (3.4) 45 (30.6) <0.001
Infections, n (%) 9 (10.2) 37 (25.2) 0.005
In-hospital mortality, n (%) 12 (13.6) 28 (19.0) 0.112
Failure to control
bleeding, n (%)
1 (1.1) 7 (4.8)
Sepsis, n (%) 3 (3.4) 7 (4.8)
Multiple organ failure, n (%) 8 (9.1) 14 (9.4)
Abbreviations: APC, argon plasma coagulation; COPD, chronic obstructive
pulmonary disease; ESRD, end-stage renal disease; EV, esophageal varices;
GOV, Gastroesophageal varices; IGV, Isolated gastric varices; MELD, Model
for End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug;
WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; PT, prothrombin
time
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negative bacilli in 15 patients (Klebsiella pneumoniae
in 7; Escherichia coli in 6; Pseudomonas aeruginosa in 2)
and gram-positive cocci in 6 patients (Streptococcus pneu-
moniae in 4; Staphylococcus aureus in 1; Enterococcus fae-
calis in 1). The risk factors for bacterial infection were
higher Child-Pugh score (HR = 1.251; 95 % CI = 1.080–
1.449; p = 0.003) and active alcoholism (HR = 1.882; 95 %
CI = 1.045–3.388; p = 0.035). Antibiotic prophylaxis played
a significant role to prevent infections (HR = 0.377; 95 %
CI = 0.180–0.786; p = 0.009) (Table 3).
In-hospital death occurred in 40 patients (17 %). Causes
of death were hypovolemic shock in 8 patients (1 in the
Table 2 Univariate and multivariate analysis of potential risk factors for rebleeding in patients with peptic ulcer bleeding after
endoscopic treatment
Variable Univariate analysis Multivariate analysis
Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
Age 0.991 (0.971–1.012) 0.383
Male gender 2.882 (1.141–7.283) 0.025 2.639 (0.968–7.198) 0.058
Etiology of liver cirrhosis
Alcoholic 1.001 (0.521–1.924) 0.998
Viral hepatitis 1.086 (0.790–1.494) 0.610
Cryptogenic 0.715 (0.369–1.384) 0.319
Decompensated cirrhosis 1.559 (0.881–2.758) 0.127
Rockall score 1.071 (1.031–1.111) <0.001 1.069 (1.022–1.120) 0.004
MELD score 1.141 (0.964–1.351) 0.126
Child-Pugh score 1.321 (1.126–1.548) 0.001 1.128 (0.923–1.378) 0.238
Other comorbidities
Diabetes mellitus 1.244 (0.689–2.249) 0.469
Hypertension 0.688 (0.378–1.255) 0.233
CVD 0.948 (0.230–3.912) 0.941
Stroke 1.360 (0.422–4.382) 0.607
ESRD 1.246 (0.448–3.470) 0.673
COPD 0.495 (0.145–1.683) 0.260
Use of NSAID or aspirin 1.479 (0.586–3.734) 0.408
Smoking 1.362 (0.771–2.405) 0.287
Active alcoholism 1.585 (0.898–2.799) 0.112
WBC (109/l) 1 0.886
Hb (g/dl) 0.990 (0.869–1.128) 0.880
PLT (109/l) 0.997 (0.992–1.002) 0.260
PT (s) 1.286 (0.749–2.207) 0.362
Creatinine (mg/dl) 1.063 (0.966–1.171) 0.213
Albumin (g/l) 0.635 (0.402–1.005) 0.053
Total bilirubin 1.068 (1.012–1.128) 0.017 1.042 (0.967–1.122) 0.277
Blood units transfused 1.032 (1.015–1.050) <0.001 1.019 (1.002–1.037) 0.031
Hypovolemic shock on admission 1.143 (0.453–2.887) 0.777
High risk bleeding stigmata at ulcer base 1.103 (0.407–2.989) 0.848
Time (h), bleeding to endoscopic treatment 0.989 (0.959–1.039) 0.940
Combined treatment of endoscopic hemostasis 0.941 (0.521–1.700) 0.840
Bacterial infection 1.974 (1.081–3.607) 0.027 1.012 (0.527–1.941) 0.972
Antibiotic prophylaxis 0.090 (0.028–0.291) <0.001 0.082 (0.025–0.267) <0.001
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, Cardiovascular disease; ESRD, end-stage renal disease; MELD, Model for
End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug; WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; PT, prothrombin time
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antibiotic group and 7 in control group), sepsis in 10
patients (3 and 7 patients, respectively) and multiple organ
failure in 22 patients (8 and 14 patients, respectively).
There was no significant difference in mortality during
hospitalization between patients treated with intraven-
ous ceftriaxone (n = 12, 13.6 %) and those in the control
group (n = 28, 19 %). The observed survival was virtually
identical for both groups (p = 0.112; Table 1). The results
of the univariate and multivariate analyses for independ-
ent risks of death after acute PUB are summarized in
Table 4. The results of univariate analysis showed that de-
compensated cirrhosis, total bilirubin level, Rockall score,
Table 3 Univariate and multivariate analysis of potential risk factors for infection in patients with peptic ulcer bleeding after
endoscopic treatment
Variable Univariate analysis Multivariate analysis
Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
Age 0.989 (0.968–1.010) 0.286
Male gender 1.171 (0.580–2.363) 0.660
Etiology of liver cirrhosis
Alcoholic 1.869 (1.015–3.441) 0.045 1.842 (0.899–3.774) 0.095
Viral hepatitis 0.769 (0.572–1.035) 0.083
Cryptogenic 0.933 (0.582–1.498) 0.775
Decompensated cirrhosis 2.339 (1.273–4.298) 0.006 1.688 (0.707–4.043) 0.239
Rockall score 1.275 (1.048–1.552) 0.015 1.141 (0.944–1.381) 0.173
MELD score 1.061 (1.022–1.100) 0.002 1.048 (0.988–1.111) 0.121
Child-Pugh score 1.289 (1.113–1.493) 0.001 1.251 (1.080–1.449) 0.003
Other comorbidities
Diabetes mellitus 1.272 (0.693–2.338) 0.437
Hypertension 0.971 (0.537–1.757) 0.923
CVD 0.483 (0.066–3.510) 0.472
Stroke 0.412 (0.057–2.990) 0.380
ESRD 1.661 (0.402–6.860) 0.483
COPD 1.981 (0.837–4.686) 0.120
Use of NSAID or aspirin 0.127 (0.018–0.925) 0.042 0.182 (0.025–1.336) 0.094
Smoking 1.301 (0.725–2.335) 0.378
Active alcoholism 1.924 (1.075–3.446) 0.028 1.616 (0.789–3.310) 0.190
WBC (109/l) 1 0.804
Hb (g/dl) 0.899 (0.775–1.019) 0.090
PLT (109/l) 0.996 (0.991–1.001) 0.160
PT (second) 1.290 (0.781–2.129) 0.319
Creatinine (mg/dl) 0.958 (0.830–1.106) 0.562
Albumin (g/l) 0.921 (0.592–1.434) 0.716
Total bilirubin 1.071 (1.019–1.127) 0.008 1.006 (0.929–1.088) 0.887
Blood units transfused 1.016 (0.993–1.0140 0.181
Hypovolemic shock on admission 1.328 (0.525–3.362) 0.550
High risk bleeding stigmata at ulcer base 2.830 (0.686–11.68) 0.150
Time (h), bleeding to endoscopic treatment 1.026 (0.997–1.055) 0.077
Combined treatment of endoscopic hemostasis 0693 (0.385–1.248) 0.222
Recurrent bleeding 1.974 (1.075– 3.623) 0.028 1.601 (0.781–3.282) 0.906
Antibiotic prophylaxis 0.346 (0.167–0.719) 0.004 0.377 (0.180–0.786) 0.009
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, Cardiovascular disease; ESRD, end-stage renal disease; MELD, Model for
End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug; WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; PT, prothrombin time
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MELD score, Child-Pugh score, bacterial infection, and
recurrent bleeding were associated with an increased risk
of death. In multivariate analysis, the in-hospital mortal-
ity was remarkably dependent on Rockall score (HR =
1.884; 95 % CI = 1.477–2.404; p <0.001) and recurrent
bleeding (HR = 2.796; 95 % CI = 1.473–5.306; p = 0.002).
Subgroup analytical result for compensated and
decompensated patients
By using the Kaplan–Meier approach, the administration
of prophylactic antibiotics was not associated with
significant differences in in-hospital mortality between
our cohort (13.6 % vs. 19 %, p = 0.112 by log-rank test;
Table 4 Univariate and multivariate analysis of potential risk factors for death in patients with peptic ulcer bleeding after endoscopic
treatment
Variable Univariate analysis Multivariate analysis
Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
Age 0.981 (0.958–1.004) 0.112
Male gender 2.046 (0.902–4.639) 0.087
Etiology of liver cirrhosis
Alcoholic 1.188 (0.577–2.455) 0.641
Viral hepatitis 1.023 (0.722–1.488) 0.887
Cryptogenic 0.713 (0.366 –1.392) 0.322
Decompensated cirrhosis 2.112 (1.014–4.402) 0.046 1.259 (0.497–3.188) 0.627
Rockall score 1.638 (1.327–2.022) <0.001 1.884 (1.477–2.404) <0.001
MELD score 1.049 (1.007–1.093) 0.023 0.945 (0.875–1.020) 0.417
Child-Pugh score 1.321 (1.126–1.548) 0.001 1.252 (0.915–1.712) 0.163
Other comorbidities
Diabetes mellitus 1.163 (0.825–1.639) 0.388
Hypertension 0.826 (0.437–1.562) 0.555
CVD 1.656 (0.396–6.924) 0.490
Stroke 0.830 (0.194–3.542) 0.801
ESRD 1.462 (0.445–4.808) 0.532
COPD 0.495 (0.145–1.683) 0.260
Use of NSAID or aspirin 1.381 (0.765–2.493) 0.284
Smoking 1.040 (0.739–1.465) 0.820
Active alcoholism 1.453 (0.771–2.739) 0.248
WBC (109/l) 1 0.737
Hb (g/dl) 0.941 (0.809–1.095) 0.431
PLT (109/l) 0.997 (0.992–1.002) 0.211
PT (second) 1.355 (0.823–2.232) 0.232
Creatinine (mg/dl) 1.003 (0.857–1.174) 0.972
Albumin (g/l) 0.906 (0.555–1.479) 0.692
Total bilirubin 1.056 (1.004–1.111) 0.033 0.987 (0.916–1.063) 0.731
Blood units transfused 0.989 (0.961–1.018) 0.468
Hypovolemic shock on admission 1.184 (0.420–3.341) 0.750
High risk bleeding stigmata at ulcer base 1.103 (0.407–2.989) 0.848
Time (h), bleeding to endoscopic treatment 0.972 (0.936–1.010) 0.143
Combined treatment of endoscopic hemostasis 0.966 (0.485–1.926) 0.922
Bacterial infection 1.770 (0.945–3.318) 0.075
Recurrent bleeding 2.412 (1.292–4.501) 0.006 2.796 (1.473–5.306) 0.002
Antibiotic prophylaxis 0.582 (0.293–1.151) 0.121
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, Cardiovascular disease; ESRD, end-stage renal disease; MELD, Model for
End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug; WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; PT, prothrombin time
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Fig. 1). On the other hand, we observed that the
in-hospital mortality was 28.6 % in patients with decom-
pensated cirrhosis and 7.7 % in patients with compen-
sated cirrhosis (p <0.001) following acute PUB. Because
the lack of a beneficial effect may be related to the sever-
ity of liver disease, we conducted a sub-analysis on the
basis of liver decompensation among these cirrhotic
patients. The observed in-hospital mortality was virtu-
ally identical for both groups of patients with baseline
compensated cirrhosis (93.2 % vs. 91.9 %, p = 0.830 by
log-rank test; Fig. 2). However, the administration of
prophylactic antibiotics showed significantly reduction
of in-hospital mortality of patients with baseline decom-
pensated cirrhosis compared to those without antibiotic
prophylaxis (79.5 % vs. 65.6 %, p = 0.034 by log-rank test)
after subgroup analysis (Fig. 3). The predictive risk factor
associated with in-hospital death among decompensated
cirrhotic patients was Rockall score (HR, 1.623; 95 % CI,
1.204–2.187; p = 0.001). Antibiotic prophylaxis has a pro-
tective role for in-hopital death in these patients (HR,
0.395; 95 % CI, 0.173–0.899; p = 0.027). For compensated
cirrhotic patient, Rockall score (HR, 1.633; 95 % CI, 1.103–
2.417; p = 0.014) and recurrent bleeding (HR, 3.684; 95 %
CI, 1.040–13.05; p = 0.044) were the predictive factors
associated with in-hospital death (Table 5).
Discussion
Multiple factors contribute to the infection of cirrhotic
patients with upper gastrointestinal bleeding. Cirrhotic pa-
tients usually have host defense defects against bacterial
infection [16]. Furthermore, hypovolemia has been re-
ported to increase intestinal bacterial translocation and
depress reticuloendothelial system activity [17, 18]. In
addition, patients with decompensated cirrhosis have
more frequent episodes of infection than those with com-
pensated liver disease [19]. Bacterial infection is associated
with failure to control bleeding and patients with recur-
rent bleeding episodes [20]. An increase in portal pressure
and changes in hemostasis induced by infection have been
suggested as possible mechanisms [1, 21]. It has been sug-
gested that intestinal bacterial translocation plays an im-
portant role in the pathogenesis of many infections. A
meta-analysis of 12 trials comprising a total of 1241 pa-
tients with cirrhosis and gastrointestinal bleeding demon-
strated that antibiotic prophylaxis significantly decreased
the incidence of bacterial infections, re-bleeding, length of
hospitalization, and mortality [22]. Currently, antibiotic
prophylaxis is the standard care for cirrhotic patients with
acute variceal bleeding but the prescription of antibiotic
prophylaxis in cirrhotic patient with PUB has not been
well documented. In order to address this particular
issue in cirrhotic patients with PUB, we conducted this
hospital-based cohort study for further clarification.
The results of the current study proved the benefit
of antibiotic prophylaxis for bleeding peptic ulcers in
cirrhotic patients with only 9 of the 88 patients (10.8 %)
included in the antibiotic group developing bacterial infec-
tions during hospitalization. On the other hand, 37 of the
147 patients (25.2 %) in the control group suffered from a
greater number of infectious events. In the multivariate
Fig. 1 Actuarial probability of remaining survival in all cirrhotic patients after endoscopic interventions for the ceftriaxone group (antibiotic
prophylaxis group) and the nil- antibiotic prophylaxis group (control group)
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analysis, higher Child-Pugh score, active alcoholism, and
no antibiotic prophylaxis were significant predictors of
infection development. Bacterial infections have been
observed more frequently in Child-Pugh’s C patients
than in those with Child-Pugh’s A or B [23] and active
alcoholism can increase host susceptibility to bacterial
infection, probably owing to the immunocompromised
status following liver decompensation [24]. The bottom
line is, the most common pathogens cultured in cirrhotic
patients are gram-negative bacilli [15, 20]. The hypothesis
Fig. 2 Actuarial probability of remaining survival at different stages of cirrhotic patients (compensated liver cirrhosis). There was a similar probability
of survival between compensated patients who were prescribed with intravenous ceftriaxone and those without antibiotic prophylaxis (p = 0.830
by log-rank test)
Fig. 3 Actuarial probability of remaining survival at different stages of cirrhotic patients (decompensated liver cirrhosis). A significantly higher
probability of remaining survival was observed in those who were prescribed with intravenous ceftriaxone than those without antibiotic
prophylaxis (p = 0.034 by log-rank test)
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behind this could be the onset of infection by intestinal
bacterial translocation. In our study, gram-positive cocci
accounted for 28.6 % of infections. This was probably be-
cause cirrhotic patients with upper gastrointestinal bleeding
tended to receive multiple sessions of diagnostic and
therapeutic invasive procedures, which in turn resulted
in infections with gram-positive cocci [25, 26].
Overall, the ulcer rebleeding rate observed in the
current study (22.3 %) which was higher than those re-
ported in non-cirrhotic patients (3.2 %) [27] or in cirrhotic
Table 5 Univariate and multivariate analysis of potential risk factors for mortality with peptic ulcer bleeding after endoscopic
treatment at different clinical stages of cirrhotic patients (subgroup analysis)
Variable Compensated liver cirrhosis (N = 130) Decompensated liver cirrhosis (N = 105)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
p-value Hazard ratio (95 % CI) p-value p-value Hazard ratio (95 % CI) p-value
Age 0.753 0.115
Male gender 0.140 0.351
Etiology of liver cirrhosis
Alcoholic 0.136 0.639
Viral hepatitis 0.281 0.422
Cryptogenic 0.644 0.482
Rockall score 0.014 1.633 (1.103–2.417) 0.014 0.001 1.623 (1.204–2.187) 0.001
MELD score 0.713 0.151
Child-Pugh score 0.236 0.013 1.088 (0.855–1.384) 0.492
Other comorbidities






Use of NSAID or aspirin 0.386 0.128
Smoking 0.629 0.975
Active alcoholism 0.533 0.177
WBC (109/l) 0.428 0.880
Hb (g/dl) 0.921 0.463
PLT (109/l) 0.796 0.375
PT (second) 0.898 0.597
Creatinine (mg/dl) 0.766 0.869
Albumin (g/l) 0.517 0.955
Total bilirubin 0.450 0.167
Blood units transfused 0.794 0.309
Hypovolemic shock on admission 0.396 0.751
High risk bleeding stigmata at ulcer base 0.593 0.676
Time (h), bleeding to endoscopic treatment 0.734 0.085
Combined treatment of endoscopic
hemostasis
0.229 0.538
Bacterial infection 0.327 0.224
Recurrent bleeding 0.043 3.684 (1.040–13.05) 0.044 0.096
Antibiotic prophylaxis 0.830 0.042 0.395 (0.173–0.899) 0.027
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, Cardiovascular disease; ESRD, end-stage renal disease; MELD, Model for
End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug; WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; PT, prothrombin time
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patients (7 %) [28]. The higher rebleeding events may be
explained by the occurrence of a greater number of high
risk bleeding stigmata identified in all of our patients with
PUB (Forrest Ia, Ib: 51.9 % and Forrest IIa, IIb: 42.4 %)
compared with those reported by the Marmo and Rudler
groups [27, 28]. However, we observed that rebleeding
and mortality do not seem to be associated with time to
endoscopy. Although patients in the present study re-
ceived endoscopy within 24 h, mortality remains high
compared to patients without cirrhosis in the literature
[29]. The predictors for rebleeding were: a higher Rockall
score, more units of blood transfused, and no antibiotic
prophylaxis. Again, current study proved the importance
of administrating prophylactic antibiotics is crucial in pre-
venting rebleeding in cirrhotic patients. Although pres-
ence of high risk bleeding stigmata is well-established risk
factor for peptic ulcer bleeding, we didn’t find significantly
correlation with rebleeding. Several factors might contrib-
ute to the discrepant results. First, it is possible that this
retrospective analysis depended heavily on the complete-
ness of the medical records and bias could exist. However,
we reviewed endoscopic images or videos to determine
the severity of the ulcer involved if uncertain chart de-
scription of ulcer morphology was encountered. Second, it
was probably due to most ulcers belonged to high stig-
mata (Forrest Ia, Ib: 50.2 % and Forrest IIa, IIb: 38.7 %) in
all of our enrolled patients. In fact, current guidelines do
not recommend hemostatic therapy for patients with low-
risk stigmata, such as those ulcers with a clean base (For-
rest III) or ulcers with flat spots (Forrest IIc), and even
recommend early discharge in selected patients with a low
risk of rebleeding after endoscopic evaluation.
However, our study failed to show a significant differ-
ence in mortality or reduced length of hospital stay be-
tween patients who received prophylactic antibiotics and
the control group. Probably, other factors such as require-
ment for mechanical ventilation, length of stay in intensive
care unit, multiple organ dysfunction, and underlying co-
morbidities contributed to longer hospital stays and could
be important determinants other than prophylactic anti-
biotic administration. Our study also clearly showed the
increased mortality of patients with decompensated cir-
rhosis compared to those with compensated cirrhosis,
with a quadrupling tripling of mortality risk (28.6 % vs.
7.7 %). Moreover, there was still an increased mortality of
patients with decompensated cirrhosis compared with
compensated cirrhosis even among patients with anti-
biotic prophylaxis (20.5 % vs. 6.8 %). Overall, the mortality
rate in this study was 17 %. This was higher than those re-
ported in previous studies of PUB [30]. This was not sur-
prising because 44.7 % of our patients had decompensated
cirrhosis. Patients with cirrhosis who develop PUB were at
increased risk of mortality, and the risk appeared to in-
crease further as patients progressed from compensated
to decompensated cirrhosis. This could be due to the fact
that patients with decompensated cirrhosis have an in-
creased risk of developing sepsis, multiple organ fail-
ure, and death [31]. To our knowledge, our study was the
first to compare the outcomes in cirrhotic patients with
or without liver compensation who received antibiotic
prophylaxis for PUB. Because no beneficial effect of anti-
biotic prophylaxis may be attributed to the severity of
liver disease, we decided to perform a subgroup analysis
on the basis of liver compensation by dividing our pa-
tients into 2 subgroups. Our results revealed an important
message that intravenous ceftriaxone is only of benefit in
reducing mortality in decompensated cirrhotic patients
with peptic ulcer hemorrhage.
Mortality occurred in 13.6 % and 19 % of patients with
or without antibiotic prophylaxis respectively. Only 20 %
of the deaths were directly related to the bleeding episode,
whilst the remaining deaths were associated with sepsis
(n = 40, 25 %) and multi-organ failure (n = 22, 55 %). Des-
pite substantial improvement in PUB management, the
mortality in cirrhotic patients remains high, especially
among patients with advanced liver cirrhosis [32, 33]. In a
recently published study of 10,428 patients with non-
variceal upper gastrointestinal bleeding in non-cirrhotic
patients, death was associated with causes directly related
to the bleeding episode in only 29 % of cases whilst in the
remaining cases, co-morbidity played a fundamental role
[34]. In other words, most PUB-linked deaths are not dir-
ectly caused by the bleeding ulcer itself. This probably
explains why routine antibiotic prophylaxis after gastro-
intestinal bleeding, even though it significantly reduces
the incidence of bacterial infections, does not signifi-
cantly affect the mortality rate. As most mortality occurs
as a result of multi-organ failure, this suggests that
improved treatments and supportive care should be pro-
vided to prevent sepsis complications and key organ failure.
On the other hand, three patients died from uncertain
causes soon after endoscopy and they were excluded from
study. The causes of mortality could not be determined
whether they were procedure-related (suffocation, aspir-
ation pneumonia, bowel trauma, incomplete endoscopic
hemostasis, as extra), bleeding-related or other causes
such as acute myocardial infarction, brain stroke, perfo-
rated peptic ulcer, as extra. Therefore, we excluded pa-
tients who die within 24 h due to unable to analyses the
cause of mortality.
The Rockall score was found to be an independent pre-
dictor of in-hospital mortality [11]. It makes séance as it
includes both clinical and endoscopic criteria to predict
the risk of rebleeding and death. The bottom line is, we
used the MELD score, the Child-Pugh classification, and
the Rockall’s risk scoring system to assess our patients but
mortality was surprisingly not related to the severity of
liver dysfunction as expressed by either the MELD score
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or the Child-Pugh classification. Only Rockall scores were
associated with rebleeding and death. The effectiveness of
the Rockall score as a predictor of in-hospital death in
cirrhotic patients with PUB proved to be similar to that
reported in non-cirrhotic patients [35].
A major strength of this study is that it was a well-
defined consecutive registered study cohort treated by a
standard endoscopic intervention. Patients who received
antibiotic prophylaxis were defined as antibiotic group
and those who not received were used as historical
control. To provide the highest possible level of uniform-
ity and to minimize differences in the entry, only patients
who received their initial and subsequent treatment in our
unit were studied. The robustness of this study is en-
hanced by the restriction of subjects to patients without
an apparent source of infection at first bleeding episode,
strict exclusion criteria and the complete follow-up of the
cohort. The use of rebleeding, infection and death as the
main outcomes provided consistent and objective end-
points in the study. Unlike other studies, which have
included patients at differing disease stages without separ-
ate analyses, our study did evaluate the impact of liver
function on the efficacy of antibiotics.
Current study encountered some limitations. First, the
sample size was small and a single center cohort study.
Certain selection biases could exist and must be cautious
in extrapolating the results. Multicenter data with a
larger sample size is mandatory. Second, the authors also
served as data abstractors and could have been biased
because they were not blinded which was not possible in
this retrospective cohort study. Therefore, exposure bias
might be considered a limitation of this study. Third,
survivor bias may have occurred in which surviving
patients who probably had more opportunities to receive
intensive care, such as ventilator support, hemodialysis,
repeated endoscopic hemostasis and more blood product
transfusions.
Those patients who belonged to control group were
enrolled between January 1, 2008, and December 31,
2009. The antibiotic group has been routine practice to
prescribe prophylactic antibiotics to cirrhotic patients
with gastrointestinal bleeding in our hospital since 2010.
This minimized bias in our results, because both cohorts
were enrolled according to identical treatment protocol
adhering to our hospital policy in our daily practices for
PUB population even though during the different period.
Conclusions
This study confirmed the beneficial effects of antibiotic
prophylaxis in patients with cirrhosis following APU
with the reduced infections and rebleeding events. The
study also suggests that antibiotic prophylaxis could
improve survival in decompensated cirrhotic patients
following acute PUB. The Rockall score was the stron-
gest predictive factor of in-hospital mortality. Further
studies directed to explore ways to improve the overall
outcome of cirrhotic patients with PUB are mandatory.
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